Martin R S, Luong L A, Welsh N J, Eglen R M, Martin G R, MacLennan S J
Department of Molecular Pharmacology, Center for Biological Research, Neurobiology Unit, Roche Bioscience, R2 - 101, 3401 Hillview Avenue, Palo Alto, California CA 94304, USA.
Br J Pharmacol. 2000 Apr;129(8):1707-15. doi: 10.1038/sj.bjp.0703229.
This study investigated the cannabinoid receptor, known to inhibit neuronally-evoked contractions of the mouse isolated urinary bladder, in bladder sections isolated from mouse, rat, dog, pig non-human primate or human. The CB(1)-like pharmacology of the cannabinoid receptor in mouse isolated bladder observed previously was confirmed in this study by the rank order of agonist potencies: CP 55940>/=WIN 55212-2>HU 210>JWH 015>anandamide, the high affinity of the CB(1) selective antagonist, SR 141716A (apparent pK(B) 8.7), and the low affinity of the CB(2) antagonist, SR 144528 (apparent pK(B)<6.5). In these studies, SR 141716A (10-100 nM) significantly potentiated electrically-evoked contractions in this tissue by an undetermined mechanism. A similar rank order of agonist potencies was determined in rat isolated bladder sections (CP 55, 940> or =WIN 55212-2>JWH 015). In this tissue, the maximal inhibitory effect of all agonists was lower than in the mouse bladder. Indeed, the effects of both HU 210 and anandamide were too modest to quantify potency accurately. In the rat isolated bladder, SR 141716A (30 nM) or SR 144528 (100 nM), reversed the inhibitory effect of WIN 55212-2 (apparent pK(B) = 8.4 and 8.0, respectively) or JWH 015 (apparent pK(B) = 8.2 and 7.4, respectively). These findings may demonstrate pharmacological differences between the rat and mouse orthologues of the CB(1) receptor. Alternatively, they may be attributed to a mixed population of CB(1) and CB(2) receptors that jointly influence neurogenic contraction of the rat bladder, but cannot be differentiated without more selective ligands. WIN 55212-2 had no effect on electrically-evoked contractions of bladder sections isolated from dog, pig, cynomolgus monkey and human. These findings suggest that the effect of cannabinoid agonists to inhibit neurogenic contraction of the mouse and rat bladder is not conserved across all mammalian species.
本研究在从小鼠、大鼠、犬、猪、非人灵长类动物或人类分离出的膀胱切片中,对已知可抑制小鼠离体膀胱神经诱发收缩的大麻素受体进行了研究。本研究通过激动剂效力的排序顺序证实了先前在小鼠离体膀胱中观察到的大麻素受体的CB(1)样药理学特性:CP 55940≥WIN 55212-2>HU 210>JWH 015>花生四烯乙醇胺,CB(1)选择性拮抗剂SR 141716A的高亲和力(表观pK(B) 8.7),以及CB(2)拮抗剂SR 144528的低亲和力(表观pK(B)<6.5)。在这些研究中,SR 141716A(10-100 nM)通过一种未确定的机制显著增强了该组织中的电诱发收缩。在大鼠离体膀胱切片中也确定了类似的激动剂效力排序顺序(CP 55,940≥WIN 55212-2>JWH 015)。在该组织中,所有激动剂的最大抑制作用均低于小鼠膀胱。实际上,HU 210和花生四烯乙醇胺的作用都太小,无法准确量化效力。在大鼠离体膀胱中,SR 141716A(30 nM)或SR 144528(100 nM)可逆转WIN 55212-2(表观pK(B)分别为8.4和8.0)或JWH 015(表观pK(B)分别为8.2和7.4)的抑制作用。这些发现可能表明CB(1)受体的大鼠和小鼠直系同源物之间存在药理学差异。或者,它们可能归因于CB(1)和CB(2)受体的混合群体,它们共同影响大鼠膀胱的神经源性收缩,但在没有更具选择性的配体的情况下无法区分。WIN 55212-2对从犬、猪、食蟹猴和人类分离出的膀胱切片的电诱发收缩没有影响。这些发现表明,大麻素激动剂抑制小鼠和大鼠膀胱神经源性收缩的作用在所有哺乳动物物种中并不保守。